Alterity Therapeutics (ATH) H2 2024 earnings summary

Executive summary

• Achieved key milestones in clinical development, notably in Phase 2 trials for ATH434 targeting Multiple System Atrophy (MSA), with enrollment completed and positive interim data reported for advanced MSA patients.

• Expanded intellectual property portfolio, securing new patents for novel compounds addressing neurodegenerative diseases.

• Maintained strong presence at major scientific meetings, presenting data that validate the company’s approach and generate interest in ATH434.

Financial highlights

• Net loss for the year ended June 30, 2024 was A$19.1 million, compared to A$13.8 million in 2023.

• Research and development expenses increased 41.3% year-over-year to A$18.6 million.

• Cash and cash equivalents at June 30, 2024 were A$12.6 million, down from A$15.8 million the prior year.

• Accumulated deficit reached A$214.2 million.

• Received A$4.0 million in R&D tax incentive income.

Outlook and guidance

• Topline data from the ATH434-201 Phase 2 trial expected in January 2025; ATH434-202 topline data expected in the first half of 2025.

• Company intends to raise new equity funding within six months of fiscal year end to support ongoing R&D programs.